Kalbe Farma (KLBF) released 51% ownership of shares in Kalbe Milko Indonesia

ILLUSTRATION. Kalbe Farma (KLBF) transferred 51% stake in Kalbe Milko to a subsidiary.

Reporter: Kenia Intan | Editor: Wahyu T. Rahmawati

KONTAN.CO.ID – JAKARTA. Pharmaceutical issuer PT Kalbe Farma Tbk (KLBF) has sold 51% of its shares in PT Kalbe Milko Indonesia (WE), Tuesday (29/9). The shares were then absorbed by PT Sanghiang Perkasa (SHP).

With this transaction, there is a change in the composition of shareholders in US. KLBF is not registered as share owner. On the other hand, SHP is recorded as owning 51% of shares in US or the equivalent of 44,880 shares with a value of Rp 44.88 billion.

Just so you know, both of them are subsidiaries whose entire shares, either directly or indirectly, are owned by KLBF. “This transaction is the company’s step in grouping the company’s business units / subsidiaries into similar divisions,” said Kalbe Farma President Director Vidjongtius in an information disclosure, Thursday (1/10).

Further explained, through this transfer of shares, it is hoped that business processes can be more focused so as to improve product and service development. While from the internal side, coordination regarding supply chain, plant operations, distribution, and support others are expected to run more smoothly.

Also Read: Kalbe Farma (KLBF) begins distribution of Covifor, the price is IDR 3 million per vial

For your information, KLBF holds share ownership in SHP up to 99.997% of shares. On the other hand, PT Bifarma Adiluhung holds a 0.003% share ownership in SHP. Meanwhile, 99.996% of PT Bifarma Adiluhung shares are owned by KLBF.

Meanwhile for US, apart from being owned by SHP, another 49% or the equivalent of 43,120 shares worth IDR 43.12 billion is owned by PT Milko Beverage Industry.

At the end of the disclosure of information, it was explained that the Kalbe board of directors stated that the transaction did not include a conflict of interest as referred to in regulation IX.E.1 and did not include material transactions as referred to in regulation NO. IX.E.2 concerning material transactions and changes in main business activities.

Also Read: Kalbe Farma (KLBF) draws remdesivir marketing, Mirae buy trading recommendation